*|MC:SUBJECT|*
bioRN News November 2025
Christmas season is coming, and with it the latest news from our vibrant life science ecosystem

Dear *|FNAME|* *|LNAME|*,

The program for life - the biomedical convention is growing - and we are excited to share several new highlights that will make the 2026 edition more dynamic, international, and forward-looking than ever. This year’s line-up features world-class innovators in the field of Synthetic Biology. and great science in the Regional Innovations track.
We are also introducing new program elements that broaden the perspective on what drives biotech innovation today. The International Investor Panel bringing together leading global funds to discuss how smart capital accelerates the next generation of biotech breakthroughs. The new Panel on the topic of Dual Use is currently in development - addressing one of the most relevant and debated topics at the intersection of innovation, security, and responsible research. More speakers and program updates are being added - discover the evolving agenda on our website and secure your place now.
The Registration Deadline for Early Bird Tickets end 30. November! 

What else happened in November?
BIO Europe 3-5 November in  Vienna: bioRN promoted the ecosystem at the German Pavilion. As Europe's leading partnering conference, BIO-Europe once again brought together nearly 6,000 attendees from over 60 countries. A perfect place for showcasing bioRN together with six members and the German Biotech sector. 

bioRN friends Kick-off meeting to promote the life science region, 10. November 2025: Initiated by bioRN, representatives from academia and industry gathered to discuss joint activities. Several work packages have already been defined, which are to be advanced within the framework of working groups. An important and powerful initiative that will contribute significantly to the growth of the ecosystem! 

bioRN Lounge, 25. November - the last one of the year: The last bioRN Lounge in the year 2025 brought together leading minds from academia and industry to explore one of the most exciting frontiers in materials science:high-resolution 3D/4D printing for the next generation of biomedical innovation.
We were thrilled to welcome Prof. Dr. Eva Blasco from Heidelberg University who shared deep insights into how her group designs adaptive, nature-inspired and sustainable polymer materials that enable ultra-precise additive manufacturing - from complex microstructures to dynamic materials with controllable depolymerisation. 

Meet bioRN in December:
1)  02. December, 12pm: bioRN M2M Member to Member interview featuring Just Evotec Biologic (zoom). Register here.
2) 11. December, 5pm: General Member Assembly of BioRN Network e.V., Tankturm Heidelberg

Don´t miss further news from the network at the bioRN website.
Find out about new bioRN events here and get the latest news about funding and growth opportunities at 05 | Opportunities.

We wish you a a peaceful Advent season!

Kind regards,

Stephanie Füller 
PR Manager

bioRN Life Science Cluster 
LinkedIn
Twitter
Website
01 | Research Highlights & News
02 | New Members
03 | Event Spotlights
04 | Event Calendar & Discounts
05 | Opportunities
06 | Open Positions
01 | Research Highlights & News

AbbVie: AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma [more]


BioMed X Announces New Neuroscience Research Collaboration in the USA [more]

DKFZ:
  • How bacteria can cause cancer: Research award for Jens Puschhof [more]
  • Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich [more]
  • How painkillers can contribute to anemia in cancer patients [more]
  • AI solutions from the DKFZ set new standards in medical image processing [more]

EMBL: 
  • New data initiative accelerates discovery and personalised care for mental health conditions [more]
  • Expanding the biological world through microscopyh [more]

Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB): Fraunhofer IGB receives approximately three million euros in funding to establish a biofabrication center [more]

Heidelberg Pharma: 
  • Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer [more]
Heidelberg University: 
  • Universität Heidelberg Succeeds with Three Funding Applications for Collaborative Research Centres [more]
  • Malaria Parasites Move on Right-Handed Helices[more]
  • With a Humboldt Professorship to Universität Heidelberg [more]
  • Universität Heidelberg with 16 “Highly Cited Researchers” [more]
  • Universität Heidelberg: New DFG Research Unit in Oncology [more]
Merck and Promega collaborate on 3D cell technology for drug discovery [more] 

Sanofi
  • Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria [more]
  • ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review [more]

SPT Labtech: 
  • SPT Labtech enables automated PacBio Kinnex full-length RNA-seq library preparation workflow on SPT’s firefly platform [more]
  • SPT Labtech and Alithea Genomics Collaborate to Automate Ultra Sensitive Single-Cell Transcriptomic Workflows [more]
Trans-Duodenal Concepts GmbH: 
  • Ovesco takes the next step in metabolic bariatric endoscopy and invests in Transduodenal Concepts [more]

02 | New Members


More information about the new members and other bioRN members can be found here.
Chatdok is an AI-powered digital health platform that allows users, healthcare professionals, and clinics to ask medical questions related to symptoms, nutrition, mental health, and more. Through video consultations, patients can connect with doctors, receive e-prescriptions and referrals within minutes. 
For chronic conditions, Chatdok offers dedicated tools such as Chatdok Heart (for cardiovascular health) and Chatdok Oncology (for cancer care) — combining remote monitoring, AI-based insights, and professional medical support.
Experimentica is a contract research organization (CRO) providing preclinical ocular models and services to pharmaceutical, biotech, and academic clients. Since 2013, they have built a global presence with customers across North America, Europe, and Asia-Pacific. Combining advanced platforms and strong R&D expertise, they develop ocular models that answer key questions on mechanisms of action, efficacy, safety, biomarkers, and readouts – supporting the path from preclinical research to clinical development.
FGK, headquartered in Munich, provides full service for clinical studies of all phases to biotechnology, medical device, and pharmaceutical companies. With our 240+ highly qualified in-house experts in the EU, UK and US we have all knowledge and experience to support the clinical trial process from planning and approval to the final report. FGK offers full or partial services including: Clinical trial management and clinical monitoring, regulatory submissions, biostatistics, data management, eSolutions, medical writing, safety, quality assurance, pharmacovigilance, consulting services.
Galatek is a pioneer in science and technology, harnessing artificial intelligence and automation to empower the global scientific community. The company provides cutting-edge laboratory automation solutions — from liquid handling workstations and high-content imaging to fully integrated organoid culture systems — serving sectors such as life sciences, diagnostics, applied chemistry, and sustainable energy.
Jobfair GmbH specializes in temporary staffing and personnel placement, offering tailored workforce solutions for the pharmaceutical industry. With access to a broad corporate applicant pool, the company ensures efficient recruitment processes while maintaining strong regional roots at its Mannheim headquarters.
Serox GmbH has been active in the biotechnology market for nearly 20 years. The company focuses exclusively on the research and development of ligand peptides, modified and custom peptides. With extensive expertise and state-of-the-art facilities, Serox manufactures peptides of outstanding purity and reliability. Their analytical quality control ensures every product meets the highest standards. Combining scientific excellence with innovative methods, Serox empowers researchers and industry partners worldwide.

03 | Event Spotlights

04 | Event Calendar & Discounts

bioRN M2M Member to Member featuring Just Evotec Biologics
December 02, 2025 -Online  >>
 
Zukünfte-Webinar: „Chancen nutzen, Märkte erschließen – Internationalisierung als Zukunftsstrategie für die Gesundheitswirtschaft"
December 04, 2025 -Online  >>
 
BioFit 2025
December 02-03, 2025 - Strasbourg, France >>
20 % Discount on Tickets. Regular Fee Tickets end on September 25th.

 
MedFit 2025
December 02-03, 2025 - Strasbourg, France >>
20 % Discount on Tickets. Regular Fee Tickets end on September 25th.

 
Pitch Night: Life Sciences Startups
December 04, 2025 - Online  >>
 
Digital/AI (R)Evolution in Drug Development & Manufacturing
December 05, 2025 - Ulm, Germany >>
 
Biotechgate Digital Partnering
December 08-12, 2025 - Online >>
Free Premium Access for Members.
Next Generation Particle Analytics: Label-free Insights at the Single-Particle Level
December 11, 2025 - Online >>
 
Workshop: Learn from Experts – Maximize the Potential of Your Cell-Based Assays!
March 04-05, 2026 - Walldorf, Germany >>
15 % Discount for Members.

 
health.tech global summit
March 02-05, 2026 - Basel, Switzerland >>
10 % Discount for Members & Opportunity for Start-Up Partnering!

 
Bio-Europe Spring
March 23-25, 2026 - Lisbon, Portugal >>
10 % Discount for Members.

 
SaxoCell Conference 2026
June 02-03, 2026 - Dresden, Germany >>
20 % Discount for Members.

 

05 | Opportunities

In this section we provide selected information on funding calls and events. On our website in the section startup support you will find a calendar with all opportunities 
 

Open Calls:  

 
  • EP PerMed Joint Transnational Call (JTC) 2026JTC2026 - Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026)  more.
  • Call for Application OPEN UNTIL December 7: New Strategies für FEmale-Controlled Non-Hormonal Contraception more
  • Richltinie zur Förderung internationaler Verbundvorhaben im Rahmen der Nationalen Bioökonomiestrategie: EU-weite, datengestützte Lösungen für reale Herausforderungen, more.
  • KMU Innovativ Biomedizin: more.

Closings: 
  • Rubio Fund III secured €70 million in commitments, more
  • Armilar announces first closing of fund IV with €120M to invest in disruptive technologies across Iberia and Europe, more
  • Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals, more
Other: Zukünfte-Webinar: „Chancen nutzen, Märkte erschließen – Internationalisierung als Zukunftsstrategie für die Gesundheitswirtschaft", 4 December (online)  more



 

06 | Open Positions
 

BioMed X Institute in New Haven, Connecticut, USA

  • ​Group Leader / Postdoctoral Researchers / Research Assistants [more]

PROGEN:

  • Operations & Events Executive (m/w/d) – Heidelberg, Germany [more]
  • Strategic Account Manager (m/f/d) – Heidelberg, Germany [more]
  • Stellvertretende Herstellungsleitung (m/w/d) – Heidelberg, Germany [more]
Tweet Tweet
Forward Forward
Share Share

Imprint


Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
*|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*

Responsible for the content:
Dr. Julia Schaft

Editor: Stephanie Füller

Our mailing address is:
*|HTML:LIST_ADDRESS_HTML|* *|END:IF|*

Commercial Register: Mannheim, HRB 704801
VAT ID: DE 2630 64 014

unsubscribe from this list    update subscription preferences 

*|IF:REWARDS|* *|HTML:REWARDS|* *|END:IF|*